Head-to-head comparison of relative cerebral blood flow derived from dynamic [¹⁸F]florbetapir and [¹⁸F]flortaucipir PET in subjects with subjective cognitive decline.

"Declarations Ethics approval and consent to participateThe current study was approved by the Medical Ethics Committee of the Amsterdam University Medical Center. All subjects signed an informed consent form prior to participation. All procedures performed were in accordance with the ethical standards of the institutional research committee and with the 1975 Helsinki Declaration and its later amendments. Consent for publicationNot applicable. Competing interestsNo potential competing of interest relevant to this article exists. Competing interests No potential competing of interest relevant to this article exists."

"Funding Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Eli Lilly and Company, provided doses and funding for the [18F]florbetapir and [18F]flortaucipir tracers."